/
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
The business is unprofitable at the operating level (-30.17% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 1.5%, essentially flat. Margins also contracted 31.9pp. This is a business that needs a catalyst.
Free cash flow declined 224% versus the prior year, cash generation momentum has weakened. ROIC dropped from 0.89% to -17.58%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$1.64B
▲ +1.5% YoY
Net Income (TTM)
-$496M
▼ -7337.7% YoY
Op. Margin
-28.36%
▼ -31.9pp YoY
ROIC
-18.93%
▼ -18.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▼ -224.4% YoY
Op. Cash Flow (TTM)
$71M
▼ -61.1% YoY
Net Debt
$625M
Cash & Equiv.
$266M
5Y CAGR: +3.6%
Continue Research